RNA Interference Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

DelveInsight's, "RNA Interference Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 90+ pipeline drugs in the RNA Interference pipeline landscape. It covers the RNA Interference pipeline drug profiles, including clinical and nonclinical stage products. It also covers the RNA Interference therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the RNA Interference Pipeline. Dive into DelveInsight's comprehensive report today! @ RNA Interference Pipeline Outlook [https://www.delveinsight.com/sample-request/rna-interference-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the RNA Interference Pipeline Report

* On 13 August 2025, Novartis Pharmaceuticals announced a phase III study designed to evaluate safety, tolerability, and efficacy of inclisiran in children (aged 2 to
* DelveInsight's RNA Interference Pipeline report depicts a robust space with 20+ active players working to develop 90+ pipeline therapies for RNA Interference treatment.
* The leading RNA Interference Companies such as Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Amgen, Sirnaomics, Silence Therapeutics, Phio Pharmaceuticals, Medesis Pharma, Atalanta Therapeutics, Mirimus/Biogen, Mallinckrodt/Silence Therapeutics and others.
* Promising RNA Interference Therapies such as Inclisiran, Saline, I5NP, Bevasiranib and others.

Get insights into RNA Interference Clinical Trials, emerging therapies, and leading companies with DelveInsight @ RNA Interference Treatment Drugs [https://www.delveinsight.com/sample-request/rna-interference-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

RNA Interference Emerging Drugs Profile

* Vutrisiran: Alnylam Pharmaceuticals

Vutrisiran is an investigational, subcutaneously administered RNAi therapeutic in development for the treatment of ATTR amyloidosis, which encompasses both hATTR and wild-type ATTR (wtATTR) amyloidosis. It is designed to target and silence specific messenger RNA, potentially blocking the production of wild-type and variant transthyretin (TTR) protein before it is made. Quarterly, and potentially biannual, administration of vutrisiran may help to reduce deposition and facilitate the clearance of TTR amyloid deposits in tissues and potentially restore function to these tissues. Vutrisiran utilizes Alnylam's Enhanced Stabilization Chemistry (ESC)-GalNAc-conjugate delivery platform, designed for increased potency and high metabolic stability that may allow for infrequent subcutaneous injections.

* Cemdisiran: Alnylam Pharmaceuticals

Cemdisiran is an investigational RNAi therapeutic targeting the C5 component of the complement pathway in development for the treatment of complement-mediated diseases. The complement system plays a central role in immunity as a protective mechanism for host defense, but its dysregulation results in life-threatening complications in a broad range of human diseases including paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic-uremic syndrome (aHUS), myasthenia gravis, neuromyelitis optica, and membranous nephropathy, amongst others. Complement component C5, which is predominantly expressed in liver cells, is a genetically and clinically validated target; loss of function human mutations are associated with an attenuated immune response against certain infections and Intraveneous anti-C5 monoclonal antibody (mAb) therapy has demonstrated clinical activity and tolerability in a number of complement-mediated diseases. A subcutaneously administered RNAi therapeutic that silences C5 represents a novel approach for the potential treatment of complement-mediated diseases. Cemdisiran utilizes Alnylam's ESC-GalNAc conjugate technology, which enables subcutaneous dosing with increased potency and durability and a wide therapeutic index. The safety and efficacy of cemdisiran have not been evaluated by the U.S. Food and Drug Administration or any other health authority. Alnylam's partner Regeneron initiated Phase III studies of cemdisiran and pozelimab combination in myasthenia gravis and paroxysmal nocturnal hemoglobinuria.

* SR061: Suzhou Ribo Life Science

Designed as a siRNA, SR061 inhibits the expression of the Caspases 2 gene via RNAi mechanism by stopping retinal ganglion cell (RGC) apoptosis and secondary axonal degeneration, thereby preventing further deterioration of vision and visual field in the diseases and achieving therapeutic effect of vision protection. SR061 holds the potential of becoming the First-In-Class neuroprotective agent being developed to treat non-arteritic anterior ischemic optic neuropathy (NAION), for which there is no standard therapy at present. One Phase I/IIa clinical study and one Phase II/III international multi-center clinical study (including 34 Chinese subjects) have been completed. A phase III confirmatory clinical study has been carried out in the group of patients, and the IND application is being prepared.

* ARO-APOC3: Arrowhead Pharmaceuticals

ARO-APOC3 is a subcutaneously administered RNAi therapeutic designed to reduce the production of Apolipoprotein C-III (Apoc-III), a component of triglyceride-rich lipoproteins (TRLs) including VLDL and chylomicrons, and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of Apoc-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. It is currently being developed as a potential treatment for patients with severe hypertriglyceridemia (SHTG), familial chylomicronemia syndrome (FCS), and mixed dyslipidemia. Arrowhead's investigational RNA interference (RNAi) therapeutic is currently under phase III trial for FCS and phase II for mixed dyslipidemia and SHTG. Furthermore, Arrowhead has successfully completed the phase I trial for hypertriglyceridemia and FCS.

* DCR-PHXC: Dicerna Pharmaceuticals

DCR-PHXC is the only RNAi investigational drug in development for the treatment of all types of primary hyperoxaluria (PH), and the most advanced product candidate utilizing Dicerna's GalXC Trademark technology. GalXC is a proprietary platform invented by Dicerna scientists to discover and develop next-generation RNAi-based therapies designed to silence disease-driving genes in the liver. Dicerna is evaluating DCR-PHXC in the PHYOX Trademark clinical trial program. The trial is currently under different phases.

The RNA Interference Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of RNA Interference with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for RNA Interference Treatment.
* RNA Interference Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* RNA Interference Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the RNA Interference market

Explore groundbreaking therapies and clinical trials in the RNA Interference Pipeline. Access DelveInsight's detailed report now! @ New RNA Interference Drugs [https://www.delveinsight.com/sample-request/rna-interference-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

RNA Interference Companies

Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Amgen, Sirnaomics, Silence Therapeutics, Phio Pharmaceuticals, Medesis Pharma, Atalanta Therapeutics, Mirimus/Biogen, Mallinckrodt/Silence Therapeutics and others.

RNA Interference pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical

RNA Interference Products have been categorized under various Molecule types such as

* Oligonucleotide
* Peptide
* Small molecule

Learn about new RNA Interference drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ RNA Interference Market Drivers and Barriers [https://www.delveinsight.com/sample-request/rna-interference-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the RNA Interference Pipeline Report

* Coverage- Global
* RNA Interference Companies- Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Amgen, Sirnaomics, Silence Therapeutics, Phio Pharmaceuticals, Medesis Pharma, Atalanta Therapeutics, Mirimus/Biogen, Mallinckrodt/Silence Therapeutics and others.
* RNA Interference Therapies- Inclisiran, Saline, I5NP, Bevasiranib and others.
* RNA Interference Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* RNA Interference Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Download DelveInsight's in-depth RNA Interference Pipeline report today! @ RNA Interference Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/rna-interference-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* RNA Interference: Overview
* Pipeline Therapeutics
* RNA Interference Therapeutic Assessment
* RNA Interference- DelveInsight's Analytical Perspective
* Late Stage Products (Pre-Registration)
* Vutrisiran: Alnylam Pharmaceuticals
* Drug profiles in the detailed report.....
* Last Stage Products (Phase III)
* Cemdisiran: Alnylam Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name : Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* RNA Interference Key Companies
* RNA Interference Key Products
* RNA Interference- Unmet Needs
* RNA Interference Market Drivers
* RNA Interference Barriers
* RNA Interference Future Perspectives and Conclusion
* RNA Interference Analyst Views
* RNA Interference Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=rna-interference-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/rna-interference-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.